Esperion Secures Cholesterol Drug Monopoly to 2040 in Key Settlement

ANN ARBOR, MI – February 17, 2026 – Esperion Therapeutics has solidified a nearly 14-year market exclusivity for its flagship cholesterol-lowering drugs, NEXLETOL and NEXLIZET, after reaching a critical patent litigation settlement with generic drug maker Alkem Laboratories. The agreement, announced today, prevents Alkem from launching a generic version in the United States before April 19, 2040, effectively shielding Esperion’s primary revenue stream from competition well into the next decade.

The settlement marks the fifth successful defense of its intellectual property by the Michigan-based biopharmaceutical company, which has systematically resolved challenges from generic manufacturers seeking to introduce cheaper alternatives. This latest victory underscores a deliberate and aggressive legal strategy that has become central to the company’s long-term financial stability and growth prospects, providing significant certainty for investors and partners. However, the extended protection for these non-statin therapies also raises questions about the future of drug affordability and patient access in the competitive cardiovascular market.

Building a Patent Fortress

Esperion’s agreement with Alkem is the latest brick in a formidable "patent fortress" built around its key commercial assets. The company has now neutralized threats from five separate Abbreviated New Drug Application (ANDA) filers. Previous settlements with Dr. Reddy's Laboratories, Accord Healthcare, Micro Labs, and Hetero Labs all concluded with the same 2040 market entry date, demonstrating a consistent and unyielding defense of its patents.

This legal bulwark protects a rapidly growing revenue engine. Esperion’s financial performance has shown remarkable acceleration, with total revenue for 2024 hitting $332.3 million, an 186% surge from the previous year. Preliminary results for 2025 project total revenue to climb as high as $408 million. The U.S. net product revenue from NEXLETOL and NEXLIZET alone is expected to reach up to $160 million for 2025, a year-over-year increase of as much as 38%.

By locking in nearly a decade and a half of additional market protection, Esperion has secured this vital income stream, which is crucial for a company still navigating its path to sustained profitability. Despite impressive revenue growth, the company has reported negative profit margins, highlighting the importance of maximizing returns from its on-market products. The market has responded favorably to this strategy; the company's stock has often seen bullish momentum following announcements of these patent dispute resolutions, reflecting investor confidence in the long-term value proposition.

While five challengers have been addressed, patent litigation remains ongoing against four other generic manufacturers: Aurobindo Pharma, MSN Pharmaceuticals, Renata Limited, and Sandoz Inc. The company has not provided a timeline for these cases, but its track record suggests a strong resolve to defend its exclusivity to the fullest extent.

The Price of Exclusivity

The success of Esperion's legal strategy has a direct impact on the broader healthcare landscape, particularly for patients and payers. With an approximate annual wholesale price of over $3,600 when they first launched, NEXLETOL and NEXLIZET represent a significant cost. The delay of generic competition until 2040 means that more affordable versions of bempedoic acid—the active ingredient—will remain off the market for an extended period.

This situation exemplifies the persistent tension within the pharmaceutical industry between rewarding innovation with market protection and the public health need for affordable medicines. "Every year that a generic is delayed is another year of high costs for the healthcare system and for patients who may struggle with co-pays," noted one healthcare policy analyst. While patent protection is designed to allow companies to recoup substantial R&D investments, extended monopolies can strain budgets and limit access for underinsured or uninsured populations.

NEXLETOL and NEXLIZET are positioned as important oral, non-statin alternatives for patients who cannot tolerate statins or require additional LDL-cholesterol reduction. The absence of a generic equivalent for another 14 years places greater financial responsibility on insurance plans and individuals seeking these specific treatments.

Expanding Access Amidst Patent Battles

Even as it defends its pricing power, Esperion has been actively working to broaden the market and improve patient access for its therapies. A pivotal development came in March 2024, when the U.S. Food and Drug Administration (FDA) approved significantly expanded labels for both NEXLETOL and NEXLIZET.

The new indications include cardiovascular risk reduction and LDL-C lowering in a much wider group of patients, covering both primary prevention (those without a prior cardiovascular event) and secondary prevention. Crucially, the labels removed the requirement for patients to be on a statin, making them the only LDL-lowering non-statin therapies approved for cardiovascular risk reduction that can be taken with or without a statin. This single change dramatically expanded the potential patient base to over 70 million people in the U.S.

In parallel, Esperion has secured broader payer coverage. By late 2024, the company reported that its updated management criteria covered over 173 million lives across commercial, Medicare, and Medicaid plans. In a significant win, both drugs were added to the U.S. Department of Defense Uniform Formulary as preferred agents in January 2025, granting access to nine million covered individuals. The company is also supporting this push with enhanced patient access programs, including reduced co-pays, to drive prescription growth and remove financial hurdles at the pharmacy counter.

Fueling the Innovation Pipeline for 'Vision 2040'

The secured revenue from its cholesterol franchise is not just an end in itself but a critical enabler of Esperion's long-term strategy, dubbed "Vision 2040." The financial stability afforded by the patent settlements is intended to fuel a new wave of innovation, transforming Esperion into a multi-product global company.

A key part of this future is advancing its leadership in ACLY biology, the mechanism behind bempedoic acid. The company is developing two triple-combination therapies that pair bempedoic acid and ezetimibe with widely used statins, atorvastatin and rosuvastatin. These single-pill combinations are projected to achieve LDL-C lowering of over 60%, putting them in direct competition with powerful but costly injectable PCSK9 inhibitors.

Furthermore, Esperion is looking to diversify beyond cardiometabolic disease. Its pipeline includes ESP-2001, a novel candidate for Primary Sclerosing Cholangitis (PSC), a rare and serious liver disease with no approved treatments. First-in-human trials for this candidate are planned for 2026. This move into rare hepatic and renal diseases represents a strategic expansion that would be difficult to fund without the predictable, long-term revenue guaranteed by the NEXLETOL and NEXLIZET patent shield. As Esperion executes its growth plan, its ability to successfully defend its intellectual property will remain the bedrock of its ambitious future.